The LabSolutions sentencing shows that a laboratory’s most dangerous liability may sit entirely outside the lab itself — in the broker contracts, telemedicine platforms, and call-center scripts that generated the orders in the first place. Buyers who diligence only the lab miss the risk.
By Noah Green CPA CFE
This article is general due diligence education for buyers, investors, lenders, and operators. It is not legal advice. Enforcement posture, docket status, restitution, and sentencing can change. Verify current posture before publication or reliance.
The Short Version
DOJ announced that LabSolutions owner Minal Patel was sentenced on Aug. 18, 2023 to 27 years after a trial conviction in a Medicare genetic-testing fraud scheme brought as part of Operation Double Helix. According to the DOJ sentencing release, Patel conspired with patient brokers, telemedicine companies, and call centers to target Medicare beneficiaries, paid kickbacks for test orders, and knew that doctors approved medically unnecessary tests without ever treating the patients whose samples were submitted.
DOJ described over \$463 million billed to Medicare and over \$187 million paid by Medicare. Both figures come from the public DOJ sentencing release and should be cited to that source only.
For buyers and investors, the diligence lesson is direct: lab revenue quality depends on the order source. Marketing contracts, telemedicine relationships, and call-center scripts can determine whether the revenue is defensible or whether it is built on a foundation that a federal jury will later characterize as a kickback scheme. A clean income statement does not answer that question. A thorough order-source trace does.
The gap between \$463 million billed and \$187 million paid is itself a diligence data point. Medicare’s claim-editing and payment controls rejected more than half the submitted claims. That rejection rate is not evidence of the lab’s restraint. It is evidence of the scale of the submission attempt and the portion of that attempt that Medicare’s systems caught before payment. The portion that was paid is the government’s loss figure and the restitution baseline. For a buyer evaluating a laboratory in this space, both numbers matter.
Related SPP reading: DOJ healthcare fraud diligence guide and Compass Detox and WAR Network case study.
Public Posture
The DOJ sentencing release, archived at the Office of Public Affairs, states that Patel was sentenced on Aug. 18, 2023 following trial conviction. The release identifies the case as part of Operation Double Helix, a dedicated DOJ enforcement initiative targeting Medicare fraud in the genetic-testing and laboratory sector.
Use convicted and sentenced language for Patel and LabSolutions as reflected in the DOJ release. Do not generalize those findings to unrelated laboratories, marketers, or telemedicine companies that were not named in the release. The DOJ 2024 National Health Care Fraud Enforcement Action release confirms that genetic testing and laboratory fraud remained an active enforcement priority through at least 2024, with 193 defendants charged nationally in that single action and over \$275 million in alleged losses described across the full action.
Posture verification date for this article is June 2, 2026. Readers should verify whether any related civil recovery, forfeiture judgment, or collateral enforcement action has been publicly announced since the August 2023 sentencing before relying on this article for any specific transaction. The DOJ sentencing release is the controlling public document for the facts stated here. Any figures or characterizations that go beyond that release require independent verification against a separate primary source.
The Mechanism: How Order-Source Fraud Works in a Lab
Understanding why the LabSolutions case matters for buyers requires understanding the mechanism DOJ described, not just the outcome.
According to the DOJ sentencing release, the scheme worked roughly as follows. Patient brokers and call centers identified Medicare beneficiaries, often through telemarketing or other outreach. Those beneficiaries were then connected to telemedicine companies whose physicians approved genetic-testing orders. DOJ said Patel knew that the approving physicians had no treating relationship with the patients and that the tests were medically unnecessary. Kickbacks were paid at each step in the referral chain to keep the orders flowing to LabSolutions.
The lab itself processed the samples and submitted the claims to Medicare. From a purely operational standpoint, the lab was doing what labs do: receiving samples, running tests, and billing for results. The fraud was not in the lab’s technical operations. It was in the order-generation infrastructure that sat upstream of the lab.
That architecture is the diligence problem. A buyer reviewing LabSolutions’ financials would have seen Medicare reimbursement revenue, test volume, and margins. Nothing in those numbers would automatically reveal that the orders were generated through a kickback network. The revenue looked real because Medicare paid it. The risk was invisible unless the buyer traced each order back to its source and asked whether a legitimate treating-provider relationship existed.
This is why the DOJ release matters as a diligence teaching document, not just as a sentencing record. It describes a revenue model that is structurally indistinguishable from legitimate lab marketing until you examine the contracts, the scripts, the consent records, and the treating-provider relationships behind each order.
The structural separation between the lab’s operations and the order-generation infrastructure also creates a documentation problem. The lab’s internal records will show sample receipt, test processing, and claim submission. They will not show what happened before the sample arrived. The broker contracts, call-center scripts, telemedicine encounter records, and patient consent forms are held by the upstream parties, not by the lab. A buyer who limits diligence to the lab’s own records will not find the risk because the risk is not in those records.
This means that a complete diligence process for a laboratory with material telemedicine or broker-sourced revenue requires obtaining and reviewing documents from parties outside the lab. That is a more complex and time-consuming process than standard financial diligence. It is also the only process that can actually surface the risk.
The Anti-Kickback Statute, 42 U.S.C. 1320a-7b(b), prohibits offering, paying, soliciting, or receiving remuneration to induce or reward referrals of items or services covered by federal health care programs. The statute applies to the full referral chain, not just to the final billing entity. A lab that pays a broker who pays a call center that recruits a Medicare beneficiary who is then connected to a telemedicine physician who approves a test is participating in a referral chain that DOJ has characterized as a kickback scheme when the economic structure of that chain is designed to generate orders rather than to serve patient care. The label on the contract does not change that analysis.
Warning Signs for Buyers
The following patterns, drawn from the conduct described in the DOJ sentencing release, should trigger deeper diligence in any laboratory or diagnostic business acquisition.
Order concentration in telemedicine or broker channels. If a material share of test orders originates from telemedicine platforms, marketing companies, or third-party referral sources rather than from established treating clinicians, the buyer must understand the economic terms of those relationships and whether they are structured to influence order volume. Concentration above 20 to 30 percent of revenue in any single non-treating referral channel warrants a full contract and compliance review of that channel before closing.
Volume-linked compensation in marketing contracts. Contracts labeled as marketing, lead generation, or patient outreach that pay per test ordered, per sample received, or per claim submitted are structurally similar to the kickback arrangements DOJ described. The contract title does not determine the legal character of the arrangement. The economic structure does. A flat-fee marketing arrangement that is renegotiated upward each time order volume increases is functionally volume-linked even if the contract does not say so. Review payment history alongside contract terms.
Ordering providers with unusual volume, geography, or specialty patterns. If a small number of providers account for a disproportionate share of orders, or if ordering providers are located far from the patients whose samples they approved, or if the ordering specialty does not align with the test type, those patterns warrant explanation. In the LabSolutions fact pattern, DOJ described physicians approving orders without treating the patients. Anomalous provider patterns are a proxy indicator for that risk. A provider ordering genetic panels for patients in multiple states from a single-state practice location is a pattern that requires a specific explanation.
Standardized test panels rather than patient-specific orders. Legitimate genetic testing is ordered in response to a specific clinical question for a specific patient. If the lab’s order patterns show that most patients received the same panel regardless of diagnosis or clinical history, that uniformity suggests the orders were driven by something other than individual medical necessity. Pull a frequency distribution of test panels ordered. If the top three panels account for more than 70 percent of orders and the patient population is diagnostically diverse, that concentration is a finding.
Weak or missing patient consent documentation. If the lab cannot produce consent records that match the outreach method used to identify the patient, or if consent forms are generic and do not reflect the patient’s actual understanding of the test, that gap is a red flag. In a scheme involving call centers and telemarketing, consent records are often the weakest link in the documentation chain. Ask specifically how consent was obtained, who obtained it, and where the records are stored. If the answer is that the upstream broker or telemedicine company holds the consent records, request those records directly.
Test results that were not returned or used in treatment. If a material share of test results were never transmitted to a treating provider, or if there is no evidence that results affected clinical decisions, medical necessity for those tests is difficult to defend. DOJ described tests ordered without a treating relationship. The result-use pattern is a downstream indicator of that problem. Review result-transmission logs and look for results that were generated but never acknowledged by a provider.
Rapid revenue growth without corresponding growth in treating-provider relationships. Legitimate lab growth is usually tied to expanding relationships with clinicians who order tests as part of patient care. Revenue growth driven primarily by broker or telemedicine channel expansion, without a corresponding increase in the treating-provider base, is a structural warning sign. Build a year-over-year comparison of revenue growth against treating-provider count growth. If revenue grew 40 percent while the treating-provider base grew 5 percent, the growth was not driven by clinical relationships.
Compliance program gaps around Anti-Kickback Statute safe harbors. If the lab’s compliance program does not include a documented analysis of whether its marketing and referral arrangements satisfy applicable Anti-Kickback Statute safe harbors, that gap suggests the arrangements were not designed with legal defensibility in mind. Ask for the compliance program documentation, the most recent compliance audit, and any outside counsel opinions on referral arrangements. Absence of those documents is itself a finding.
Prior government correspondence that was not disclosed. Any Medicare audit letter, Unified Program Integrity Contractor request, Targeted Probe and Educate review, or government subpoena that was not disclosed in the seller’s representations is a serious red flag. Labs operating in the genetic-testing space have been subject to heightened Medicare scrutiny since at least the period covered by Operation Double Helix. A lab in this space that has never received any government correspondence is either very small or has not been forthcoming in the diligence process.
Diligence Tests Before Signing or Before the Wire
The following tests are designed to surface order-source risk before a transaction closes. They are not a complete diligence checklist. They are the tests most directly responsive to the risk pattern DOJ described in the LabSolutions case.
Test 1: Order-Source Trace on a Stratified Claim Sample
Pull a stratified random sample of Medicare claims covering at least the prior 24 months. For each claim in the sample, trace the order back to the patient, the ordering provider, the referring source, the contract under which the referral was made, and the medical record that supported the order. Document the chain for each sampled claim. If the chain cannot be completed for a material share of the sample, that is a finding, not a gap to be explained away.
The sample should be stratified by payer, test type, ordering provider, and referral source. Do not allow the seller to select the sample. Use a random selection methodology and document it. A sample of 50 to 100 claims is a starting point. If the initial sample reveals anomalies, expand the sample before drawing conclusions.
For each claim in the sample, the completed trace should produce a document package that includes the patient’s Medicare enrollment record, the ordering provider’s Medicare enrollment record, the medical record entry that supports the order, the consent form, the result-transmission record, and the contract or arrangement under which the referral was made. If any element of that package is missing for a sampled claim, document the gap and escalate.
Test 2: Treating-Provider Relationship Confirmation
For each ordering provider in the sample, confirm that the provider had a legitimate treating relationship with the patient at the time of the order. This means verifying that the provider had access to the patient’s medical history, that the patient had a clinical encounter with the provider before the order was placed, and that the order was documented in the patient’s medical record as responsive to a specific clinical question.
Telemedicine-sourced orders require particular scrutiny. A telemedicine encounter that consists of a brief questionnaire followed by a standardized panel order is not the same as a treating-provider relationship. Review the telemedicine platform’s clinical protocols, the encounter documentation, and the provider’s compensation structure to assess whether the encounter was designed to generate orders or to provide care. Ask specifically whether the telemedicine platform’s providers were compensated per encounter, per order, or on a salary basis. Per-order compensation is a structural red flag.
Also verify the duration and content of telemedicine encounters for sampled orders. An encounter that lasted less than five minutes and resulted in a multi-panel genetic test order is not consistent with a genuine clinical evaluation. Request encounter duration logs if available.
Test 3: Broker and Telemedicine Contract Review
Obtain and review every contract with a marketing company, patient broker, telemedicine platform, call center, or other third-party referral source. For each contract, document the compensation structure, the volume metrics if any, the compliance representations, the termination provisions, and whether the arrangement was reviewed by outside counsel for Anti-Kickback Statute compliance.
Request all amendments, side letters, and informal arrangements. Ask specifically whether any compensation was paid outside the written contract. Review invoices and payment records against contract terms to identify any payments that do not match the documented structure. A contract that pays a flat monthly fee but is accompanied by invoices that vary with order volume is a contract that is not being performed as written.
If the seller cannot produce compliance counsel review for material referral arrangements, treat that as a significant gap. Arrangements that were never reviewed for legal defensibility were likely not designed to be defensible. Ask when each arrangement was first entered into, whether it was renewed, and whether any arrangement was terminated and why. Terminated arrangements may have been terminated because of compliance concerns that were never documented.
Test 4: Call-Center and Marketing Script Review
If the lab used call centers or telemarketing to identify patients, request the scripts, training materials, and call recordings if available. Review the scripts for language that suggests patients were recruited for testing rather than referred by a treating provider. Look specifically for scripts that describe the test as free, that minimize the patient’s role in the clinical decision, or that do not accurately describe the nature of the test or its clinical purpose.
Patient consent forms should be reviewed alongside the scripts. If the consent form does not match the outreach method, or if patients were not informed that their samples would be sent to a specific lab, the consent documentation does not support the claim. A consent form that was signed before the patient spoke with any clinical provider is a consent form that preceded the clinical evaluation, which inverts the proper sequence.
Also review any marketing materials used to recruit patients. Materials that describe genetic testing as a free benefit, as a routine screening, or as something the patient’s doctor has already recommended when no such recommendation exists are materials that describe a recruitment scheme, not a clinical referral process.
Test 5: Result-Use Testing
For the sampled claims, determine whether test results were transmitted to a treating provider and whether there is any evidence that results affected clinical decisions. This can be tested by reviewing result-transmission records, provider acknowledgment logs, and follow-up encounter documentation.
If a material share of results were never transmitted, or if results were transmitted but there is no evidence of clinical follow-up, that pattern is consistent with the conduct DOJ described: tests ordered not because they were clinically necessary but because they generated reimbursable claims. A result that was generated, transmitted, and never acted upon is not evidence of fraud by itself. A pattern of results that were systematically never acted upon is a different matter.
Request the lab’s result-transmission system records and compare them against the claim file. If the lab cannot produce transmission records for a material share of sampled claims, that is a documentation gap that must be explained before closing.
Test 6: Medicare Enrollment and Exclusion Verification
Verify that the lab holds current Medicare enrollment and that no exclusion, revocation, or payment suspension is in effect. Check the OIG exclusion database and the Medicare Provider Enrollment, Chain, and Ownership System for the lab entity and all related entities. Verify that key ordering providers are not excluded or revoked.
Also verify whether the lab has received any Medicare audit correspondence, Unified Program Integrity Contractor requests, or Targeted Probe and Educate reviews. These communications are early indicators of Medicare scrutiny and should be disclosed in the diligence process. Request copies of all such correspondence and the lab’s written responses. Review the responses for accuracy and completeness. A response that omitted material information from a government auditor is a compliance failure independent of the underlying audit finding.
Check whether the lab’s Medicare enrollment has been subject to any revalidation issues, billing privilege revocations, or payment suspensions. Payment suspensions in particular are a serious indicator because Medicare suspends payments when it has a credible allegation of fraud. A lab that experienced a payment suspension and did not disclose it in the diligence process has a disclosure problem that is separate from whatever triggered the suspension.
Test 7: Litigation Hold and Subpoena History
Ask specifically whether the lab has received any subpoenas, civil investigative demands, search warrants, or government audit requests in the prior five years. Request copies of all such correspondence and the lab’s responses. A lab that has received government process and has not disclosed it in the diligence process is a serious red flag regardless of the subject matter of the inquiry.
Review the lab’s litigation hold history. If the lab has never implemented a litigation hold, that suggests either that it has never received government process or that its document-preservation practices are inadequate. Either answer requires follow-up. Ask specifically who at the lab is responsible for responding to government process and what the lab’s written policy is for preserving documents when government process is received.
Also ask whether any current or former employee has raised compliance concerns internally, whether any whistleblower complaint has been filed, and whether the lab has received any qui tam notice. Qui tam complaints under the False Claims Act are filed under seal and the lab may not know about them, but a seller who is aware of a pending qui tam complaint and does not disclose it is making a material misrepresentation in the transaction.
Test 8: Accounts Receivable Quality and Recoupment Exposure
Review the lab’s Medicare accounts receivable aging and compare it against the claim-level data from the order-source trace. Receivables that are more than 90 days old on Medicare claims are unusual because Medicare generally pays within 30 days. Aged Medicare receivables may indicate that claims are under review, subject to prepayment audit, or in a payment suspension queue.
Also assess the lab’s exposure to Medicare recoupment. If the order-source trace identifies a material share of claims that lack adequate medical necessity documentation, those claims are potentially subject to recoupment even if they have already been paid. A borrowing base or purchase price that treats paid Medicare receivables as clean assets without testing their underlying validity is a borrowing base or purchase price that may be overstated.
Request the lab’s history of Medicare overpayment demands and repayments. A lab that has received and repaid overpayment demands has a documented history of claim integrity issues. The nature and frequency of those demands is relevant to assessing whether the current receivables are similarly at risk.
How to Read the DOJ Sentencing Release as a Diligence Document
The DOJ sentencing release for the Patel / LabSolutions case is a primary source document that buyers and their counsel should read directly, not just cite. The release is available at the URL listed in the Primary Sources section below.
When reading a DOJ sentencing release for diligence purposes, focus on the following elements.
The scheme description. DOJ releases describe the conduct the government proved at trial or established through a plea. The scheme description in the LabSolutions release identifies the specific actors, the specific mechanisms, and the specific Medicare program vulnerabilities that were exploited. Each element of the scheme description is a diligence test category. If the release describes patient brokers, the diligence test is to identify and review every broker contract. If the release describes telemedicine companies, the diligence test is to review every telemedicine arrangement. The scheme description is a map of where to look.
The loss figures. The release states over \$463 million billed and over \$187 million paid. The gap between billed and paid reflects Medicare’s claim-editing and payment controls, not the lab’s restraint. The paid figure is the government’s loss and the restitution baseline. For a buyer, the paid figure represents the revenue that was generated through the alleged scheme and that is now subject to recovery, disgorgement, or successor liability analysis. The billed figure represents the full scale of the submission attempt and is relevant to assessing the lab’s intent and the scope of the conduct.
The enforcement initiative name. The release identifies Operation Double Helix as the enforcement initiative. That name signals that the case was not an isolated prosecution but part of a coordinated national effort targeting a specific fraud pattern. The DOJ 2024 National Health Care Fraud Enforcement Action release confirms that lab and genetic-testing fraud remained an active enforcement priority after the LabSolutions sentencing. A buyer acquiring a lab in this space is acquiring into an active enforcement environment, not a historical one. The enforcement initiative name is a signal to search for related cases and to assess whether the target lab’s practices resemble those described in the broader initiative.
The sentence length. A 27-year sentence after trial conviction reflects the severity with which the court viewed the conduct. That severity is relevant context for any buyer assessing whether the risk pattern is material. Courts impose sentences of that length in cases involving large-scale, deliberate, and sustained fraud. The sentence is not just a punishment for Patel. It is a public statement about the seriousness of the conduct pattern.
What the release does not say. DOJ sentencing releases describe the conduct that was charged and convicted. They do not describe every related party, every related entity, or every related transaction. A release that names one defendant does not mean that other participants in the scheme have been resolved. Related civil recovery actions, False Claims Act suits, and collateral enforcement actions may be pending or may have been resolved separately. The release is the starting point for research, not the end of it.
By the Numbers
| Metric | Public Figure or Posture | Why It Matters for Diligence | Source |
|---|---|---|---|
| Sentencing date | Aug. 18, 2023 | Establishes resolved criminal posture for Patel and LabSolutions | DOJ sentencing release |
| Sentence imposed | 27 years | Reflects severity of convicted conduct; context for risk assessment in similar lab structures | DOJ sentencing release |
| Medicare billings alleged | Over \$463 million | Scale of billed exposure; establishes the full revenue base at issue and the scope of the submission attempt | DOJ sentencing release |
| Medicare paid | Over \$187 million | Government loss figure; restitution and recovery baseline; represents revenue generated through the alleged scheme | DOJ sentencing release |
| Gap between billed and paid | Approximately \$276 million | Medicare claim-editing controls rejected more than half the submitted claims; the paid portion is the confirmed loss, not the ceiling of the attempt | DOJ sentencing release |
| Enforcement initiative | Operation Double Helix | Signals coordinated national enforcement focus on lab and genetic-testing fraud; not an isolated prosecution | DOJ sentencing release |
| 2024 national enforcement action defendants | 193 defendants charged; over \$275 million alleged | Confirms lab and healthcare fraud enforcement remained active after LabSolutions sentencing; buyers are acquiring into an active enforcement environment | DOJ 2024 National Health Care Fraud Enforcement Action release |
Source note: All figures and posture statements in this table are drawn from the public primary sources listed below. Do not add restitution, forfeiture, or collateral case details unless a separate public judgment or docket entry is verified.
Buyer / Investor Takeaway
A laboratory acquisition that does not include a full order-source trace is an incomplete diligence process. The LabSolutions case illustrates why.
The lab’s financial statements showed Medicare revenue. That revenue was real in the sense that Medicare paid it. But the revenue was generated through a network of brokers, call centers, and telemedicine companies that DOJ characterized as a kickback scheme. The lab’s margins, test volume, and payer mix would have looked attractive in a financial model. None of those metrics would have revealed the order-source risk.
Buyers should treat the order-generation infrastructure as a separate diligence workstream from lab operations. The questions are different. Lab operations diligence asks whether the lab can process samples accurately, maintain accreditation, and bill correctly. Order-source diligence asks whether the orders that generated the revenue were medically necessary, whether the treating-provider relationships were real, and whether the contracts that produced the orders are legally defensible.
Both workstreams are necessary. Neither substitutes for the other.
The practical implication for purchase price is direct. If the order-source trace reveals that a material share of revenue was generated through arrangements that cannot be demonstrated to satisfy Anti-Kickback Statute safe harbors, that revenue is not a reliable basis for valuation. It is revenue that is subject to recoupment, False Claims Act recovery, and potential successor liability. A buyer who pays a multiple of EBITDA that includes that revenue is paying for a liability, not an asset.
Representations and warranties in the purchase agreement should specifically address order-source compliance. Standard healthcare rep and warranty packages often cover Medicare enrollment, billing compliance, and exclusion status. They do not always specifically address whether the lab’s referral arrangements comply with the Anti-Kickback Statute. A buyer who relies on a general billing compliance representation without a specific Anti-Kickback Statute representation for each material referral arrangement has a gap in the contractual protection.
Escrow and indemnification structures should reflect the order-source risk. If the diligence process identifies referral arrangements that are not clearly defensible, the escrow amount and survival period should be sized to cover the potential recoupment and False Claims Act exposure, not just the standard representations and warranties tail. A 12-month survival period is not adequate protection for a Medicare fraud exposure that may not surface until a government investigation is opened years after closing.
Investors in lab roll-up platforms face the same risk at a portfolio level. If a platform acquires multiple labs that share a common order-generation infrastructure, the risk is not diversified across the portfolio. It is concentrated in the infrastructure. Diligence on a lab roll-up should include a review of the platform’s order-generation model, not just the individual lab operations. A platform that has standardized a broker-sourced or telemedicine-sourced order model across multiple labs has standardized the risk, not managed it.
Lenders extending credit against lab receivables should apply the same logic. Receivables generated through a kickback scheme are not collectible in the ordinary course. They are subject to Medicare recoupment, False Claims Act recovery, and potential disgorgement. A borrowing base that includes those receivables without testing their underlying validity is a borrowing base built on contested assets. Lenders should require order-source representations in credit agreements and should include Medicare recoupment exposure in their collateral analysis.
The practical pre-wire test is this: before the wire transfers, the buyer’s diligence file should be able to answer the following questions for a material sample of the lab’s Medicare revenue. Who found the patient? Who ordered the test? Did the ordering provider have a treating relationship with the patient? Was the test medically necessary for that patient? Did the patient consent with accurate information? Was the result used in care? Was the contract under which the referral was made reviewed for Anti-Kickback Statute compliance? If the diligence file cannot answer those questions, the wire should not transfer.
SPP Bottom Line
SPP would not value lab EBITDA without testing medical necessity, order source, and treating-provider evidence. In lab diligence, the cleanest-looking revenue line can be the one most dependent on contracts and relationships that sit entirely outside the lab and that a federal jury may later characterize as a kickback network.
The LabSolutions case is not an outlier. The DOJ 2024 National Health Care Fraud Enforcement Action confirms that genetic testing and laboratory fraud remained an active enforcement priority after the LabSolutions sentencing, with 193 defendants charged in a single national action. Buyers, investors, and lenders operating in the laboratory and diagnostic space should treat order-source diligence as a non-negotiable workstream, not an optional add-on.
The diligence file should show the full chain from patient identification to test result. If any link in that chain is missing, unexplained, or economically structured to influence order volume, that is a finding that must be resolved before closing. A finding that cannot be resolved before closing is a reason to reprice, restructure, or walk away. The LabSolutions sentencing is a 27-year reminder of what happens when that chain is built on kickbacks rather than clinical relationships.